Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

Laia Alsina1 · J. Bruno Montoro2 · Pedro Moral Moral3 · Olaf Neth4 · Marta Ortiz Pica5 · Silvia Sánchez-Ramón6 · María Presa2 · Itziar Oyagüez7 · Miguel Ángel Casado7 · Luis Ignacio González-Granado8,9

Received: 24 November 2020 / Accepted: 1 September 2021 / Published online: 21 September 2021 © The Author(s) 2021

Abstract

Primary immunodeficiency diseases (PID), which are comprised of over 400 genetic disorders, occur when a component of the immune system is diminished or dysfunctional. Patients with PID who require immunoglobulin (IG) replacement therapy receive intravenous IG (IVIG) or subcutaneous IG (SCIG), each of which provides equivalent efficacy. We developed a cost-minimization model to evaluate costs of IVIG versus SCIG from the Spanish National Healthcare System perspective. The base case modeled the annual cost per patient of IVIG and SCIG for the mean doses (per current expert clinical practice) over 1 year in terms of direct (drug and administration) and indirect (lost productivity for adults and parents/guardians of pediatric patients) costs. It was assumed that all IVIG infusions were administered in a day hospital, and 95% of SCIG infusions were administered at home. Drug costs were calculated from ex-factory prices obtained from local databases minus the mandatory deduction. Costs were valued on 2018 euros. The annual modeled costs were €4,266 lower for patients with PID who received SCIG (total €14,466) compared with those who received IVIG (total €18,732). The two largest contributors were differences in annual IG costs as a function of dosage (– €1,927) and hospital administration costs (– €2,688). However, SCIG incurred training costs for home administration (€695). Sensitivity analyses for two dose-rounding scenarios were consistent with the base case. Our model suggests that SCIG may be a cost-saving alternative to IVIG for patients with PID in Spain.

Keywords Primary immunodeficiency disease · Immune system · Immunoglobulin replacement therapy · Subcutaneous immunoglobulin · Intravenous immunoglobulin · Cost-minimization analysis

JEL Classification I11

Laia Alsina, J. Bruno Montoro, Pedro Moral Moral, Olaf Neth, Marta Ortiz Pica and Silvia Sánchez-Ramón authors have equally contributed to this work.

* Luis Ignacio González-Granado luisigon@ucm.es

1 Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
2 Pharmacy Service, Hospital Universitari Vall d’Hebron, Barcelona, Spain
3 Sección de Inmunopatología Y Enfermedades Minoritarias, Hospital Universitari I Politècnic La Fe, Valencia, Spain
4 Paediatric Infectious Diseases, Rheumatology and Immunology Unit, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
5 Hospital de Día Médico, Hospital Clínico San Carlos, Madrid, Spain
6 Departamento de Inmunología Clínica, IML, Hospital Clínico San Carlos, Universidad Complutense of Madrid, Madrid, Spain
7 Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain
8 Primary Immunodeficiencies Unit, Pediatrics, University Hospital 12 Octubre/Research Institute Hospital, 12 octubre (i+12), Madrid, Spain
9 Pediatrics, School of Medicine, Complutense University, Madrid, Spain

© Springer
Introduction

Primary immunodeficiency diseases (PID) occur when a component of the immune system is diminished or dysfunctional and may be caused by over 400 identified genetic disorders [1]. PID may result in frequent or serious infections, autoimmune disorders, systemic inflammation, and/or cancer, all of which can lead to significant morbidity and mortality [2, 3]. The prevalence of PID in Spain is estimated to be at least 4.9 per 100,000 individuals [4]. However, because this calculation is based on registry data, the actual prevalence is likely to be higher.

Typically, patients who have PID that is associated with defects in antibody production receive immunoglobulin-replacement therapy (IGRT). Various IGRT products are available in subcutaneous immunoglobulin (SCIG), facilitated SCIG (fSCIG) and intravenous immunoglobulin (IVIG) formulations in Spain. Typically, IVIG is administered by a healthcare professional in a hospital outpatient clinic once every 3–4 weeks, and SCIG is administered at home once every 1–4 weeks. IVIG and SCIG formulations offer similar levels of efficacy [5, 6], but SCIG produces fewer systemic adverse events [5, 7, 8] than does IVIG. SCIG provides the patient with the convenience to self-infuse at home, whereas IVIG does not. Facilitated SCIG treatment has two components: IgG 10% and recombinant human hyaluronidase (rHuPh20). rHuPH20 is infused first resulting in a transient and local increase in subcutaneous tissue permeability, allowing larger doses of immunoglobulin (IG) to be administered every 3–4 weeks [9–13].

Healthcare professionals and patients may consider these aspects of IVIG and SCIG treatments differently, depending on the patient’s conditions, preferences, and perceived treatment burdens. With the understanding that patient preference plays a large role in the choice of IG therapy, we sought to understand the cost implications of patients selecting home-based SCIG or hospital-based IVIG in the Spanish healthcare setting. This study calculated and compared the annual cost of IVIG and SCIG as part of the pharmaceutical services delivered by the Spanish National Healthcare System (SNS) for the treatment of PID.

Methods

General overview

A cost-minimization analysis was developed based on the decision tree shown in Fig. 1. The model included both direct (i.e., IG therapy, premedication, hospital administration, home training, dispensing) and indirect (i.e., work absenteeism) costs. The analysis was from the SNS and societal perspectives, with a time horizon of 1 year.

Because the premise of a cost-minimization analysis assumes that the therapies being compared have equivalent outcomes, a literature review was conducted to establish the therapeutic equivalence of SCIG and IVIG. Results of two studies, one being a noninferiority trial [6] and the other a meta-analysis of 47 clinical studies [5], found no differences in efficacy between SCIG and IVIG, as measured by serum IG levels and infection rates [5, 6]. Another meta-analysis of 24 observational studies also found no significant difference in overall infections or serious infections for SCIG and IVIG, although a statistically significant association between higher IG trough levels and lower infection rates was observed with SCIG but not IVIG [14]. We took a conservative approach and assumed equivalent efficacy of SCIG and IVIG for this analysis.

Population assumptions

In the model, patients receiving SCIG could receive either a conventional 20% concentration SCIG product or a 10% concentration facilitated SCIG product, and those receiving IVIG could receive either a 5 or 10% concentration product. The usage ratios of IVIG and SCIG and each treatment available in Spain in every category were determined by current expert clinical practice and are described in Online Resource 1. The ratio of 52.5% adult (≥ 19 years) and 47.5% pediatric (< 19 years) cases was based on European Society for Immunodeficiencies database estimates for Europe [4]. This ratio was applied to patients receiving IVIG and patients receiving SCIG. More detailed age-distribution assumptions are shown in Online Resource 2.

Dosing for IG therapy is based on the patient’s body weight (g/kg); therefore, the mean weight of adult and pediatric patients was included in the model to calculate IG doses. Mean weight for adults was assumed to be 70 kg,
based on Spanish Hospital Pharmacy Society (SEFH) guidelines for economic evaluations [15]. For pediatric patients, mean weight was categorized into four age groups and calculated based on data published by the Instituto de Investigación sobre Crecimiento y Desarrollo [16]. Mean weights by age group were: < 5 years, 12.38 kg; 5–9 years, 25.88 kg; 10–15 years, 47.04 kg; and 16–18 years, 62.16 kg.

Employment-status and education-level estimates were used in the calculation of social resources (e.g., work absenteeism, school absenteeism, and lost leisure time) that were consumed by the time it takes to administer IGRT. All (100%) pediatric patients were assumed to be attending school. The overall employment rate of the Spanish population is 63.74% [17]. Clinical experts from the Spanish Association of Patients with Primary Immunodeficiencies suggested approximately 70% of patients who have PID and are of working age are employed. Therefore, we multiplied the overall Spanish employment rate by 70% to calculate an estimated employment rate of 44.6% for patients aged ≥ 19 and ≤ 64 years in our study population. Parents/guardians of pediatric patients, who often must travel with their children for treatment at the hospital, were assumed to be employed at similar rates as the Spanish general population [17].

**Model inputs**

Prescribing information for each IGRT product provides a range, or interval, for dosing. Therefore, mean doses were based on current expert clinical practice and clinical guidelines [18–20]. The model assumed that patients were treatment naïve, and the recommended starting and maintenance doses of IGRT based on each product’s prescribing information were used [10, 21, 22]. In Europe, the monthly dosage ratio of IVIG to SCIG is 1:1 [23]. Due to differences in the prescribing information for conventional and facilitated SCIG, dosage and dosing frequencies were calculated separately. Dosages and dosing frequencies, also determined by current expert clinical practice, are shown in Table 1.

All IVIG infusions were assumed to be administered in a day hospital, and most SCIG infusions were assumed to be administered in the patient’s home. On the basis of current expert clinical practice, we assumed that a small percentage of patients (1–5%, depending on the product) taking SCIG would receive their infusions in a day hospital, rather than at home. The cost of the infusion in the day hospital was assumed to include all services provided, including a proportion of healthcare-provider salaries and materials used; however, capital costs were not included. The costs for the day hospital for adults (€175.45 per visit per adult patient) and pediatric patients (€228.64 per visit per pediatric patient) and time for pharmacy dispensing (€29.84) were obtained from the eSalud database of local costs, considering an average of the individual costs available [24]. eSalud is a private database proprietary of Oblikue, available by subscription. It includes data about unitary costs for health resources from different sources in Spain, such as scientific literature, official tariffs from autonomous regions, and costs estimated by the Ministry of Health. For patients receiving

| Table 1 | Facilitated SCIG, conventional SCIG, and IVIG dosage in PID |
|-----------------|-------------------------------|-----------------|-----------------|
| SCIG            | Conventional                  | IVIG            |
| Percentage of patients | Dose (g/kg) | Frequency | Percentage of patients | Dose (g/kg) | Frequency | Percentage of patients | Dose (g/kg) | Frequency |
| Starting dose   |                               |                 |                        |               |          |                        |               |          |
| Adult           | –                              | 0.40            | Every 3 weeks for 3 months | –              | 0.10     | Every 24 h for 5 days | –              | 0.40     | Every 3 weeks for 3 months |
| Pediatric       | –                              | 0.60            | Every 4 weeks for 3 months | –              | 0.10     | Every 24 h for 5 days | –              | 0.60     | Every 4 weeks for 3 months |
| Maintenance dose|                               |                 |                        |               |          |                        |               |          |
| Adult           | –                              | 0.40            | Every 4 weeks          | 60             | 0.20     | Every 2 weeks         | –              | 0.40     | Every 4 weeks               |
| Pediatric       | –                              | 0.50            | Every 4 weeks          | 40             | 0.20     | Every 7 days          | –              | 0.60     | Every 4 weeks               |
| Adjusted dosage |                               |                 |                        |               |          |                        |               |          |
| Adult 20        | 0.50                           | Every 4 weeks   | 3                      | 0.30           | Every 2 weeks | 21             | 0.50     | Every 4 weeks               |
| Pediatric 20    | 0.60                           | Every 4 weeks   | 2                      | 0.20           | Every 7 days  | 4               | 0.50     | Every 3 weeks               |

IVIG intravenous immunoglobulin, PID primary immunodeficiency diseases, SCIG subcutaneous immunoglobulin
SCIG infusions at home, experts agreed that three or four hospital training sessions (3.5 days, 2 h each day) with an experienced professional would be needed at treatment initiation to teach the patient or caregiver how to use the infusion devices and how to recognize and possibly manage adverse reactions. The total cost of the training sessions per patient (adult or pediatric) was estimated to be €694.90 (Online resource 5) based on the estimated cost of nurse consults.

The model did not account for potential differences in adherence between patients receiving SCIG and IVIG; however, such differences are likely to be small based on real-world data [25]. Nor did it allow for potential switching between SCIG and IVIG, since it was assumed that patients were correctly assessed at the start of receiving IGRT, and no patients would switch their route of administration during the 1-year period. The model assumed that all patients receiving SCIG at home would either be capable of self-administering treatment (adults) or have their caregiver administer treatment (in the case of children).

In addition, the model assumed patients or caregivers visit the hospital pharmacy at least four times (4 days) annually on average to obtain the SCIG medication. This is based on author consensus that patients or caregivers typically collect their medication every 3 months.

Due to the higher rate of systemic reactions associated with IVIG compared with SCIG [5, 7, 8], we assumed based on current expert clinical practice that 15% of patients receiving IVIG would require premedication (e.g., acetaminophen, corticosteroid, antihistamine). The premedication dosages for adult and pediatric patients receiving IVIG are shown in Online Resource 3. The cost of premedication was obtained from the manufacturer price, after applying the deduction required by Spanish Royal Decree Law (RDL) 8/2010 [26].

Daily-life indicators affected by IGRT included work absenteeism, school absenteeism, and loss of leisure time. Time consumed by IGRT included time to prepare and infuse IG and premedication as well as to travel to the day hospital and from the hospital pharmacy (Online Resource 4).

Work absenteeism for adult (≥ 19 years) patients receiving IVIG was assumed to include time spent in the day hospital and travel time to the hospital. For employed adult patients receiving SCIG, this included training sessions, SCIG infusion in the day hospital (for a small percentage of patients), and travel to the hospital for training or infusions. Preparing, performing, and cleaning up SCIG infusions at home were assumed to have no impact on work absenteeism because the patient can administer SCIG at home outside of work hours. The time spent for these activities also applied to working parents/guardians of pediatric patients. For working patients and parents/guardians of pediatric patients, an average hourly wage (€14.04) was applied to all work absenteeism time, based on National Statistics Institute data [27].

School absenteeism and lost leisure time were calculated to show the impacts of IGRT on patient’s, parent’s, and guardian’s time; however, these data were not included in the indirect cost calculation because there was no associated cost. School absenteeism included the time that pediatric (< 19 years) patients spent on preparation and infusion of IVIG and premedication, preparation and infusion of SCIG administered in a day hospital, training sessions for SCIG, and travel time. For retired or unemployed adult patients, pediatric patients, and unemployed parents/guardians caring for pediatric patients, IG infusions were assumed to affect other activities not related to work and school, including leisure time, which was considered a social loss. Leisure time could be impacted due to administration in a day hospital, training sessions, home infusions, and travel time for infusions, training, and SCIG dispensing.

All unit costs were valued in 2018 euros (€). Costs of IG therapies were determined from the ex-factory price following the application of the deduction established by RDL 8/2010 [26]. All unit costs were obtained from the Bot Plus 2.0 database [28]. Cost inflation was not calculated because the time horizon for the analysis was only 1 year.

**Analyses**

The base case considered the cost of SCIG and IVIG per the mean dose established by current expert clinical practice (Table 1) multiplied by the ex-factory price per milligram of each of the IG therapies. The total costs of SCIG and IVIG represent a weighted average of adult and pediatric patients in each group. Two scenario analyses were also conducted to model the impacts of using SEFH guidelines and current expert clinical practice. In both scenarios, IGRT dosage was calculated by vial rather than exact dose in milligrams. In scenario 1, vial adjustment was performed by adjusting to the nearest lower dosage in adult patients and the nearest higher dosage in pediatric patients, per SEFH 2011 guidance to reduce pharmacy cost and conserve drug volumes [29]. For instance, if the total calculated dosage for an adult patient ended in 0.3 g, and the smallest vial for the IG product was 0.5 g, the dose would be rounded down to the nearest whole number of grams to conserve vials. A dose ending in 0.3 g for a pediatric patient for the same product would be rounded up to the nearest 0.5 g. In scenario 2, reflecting real clinical practice, vial adjustment was carried out by rounding up to the nearest higher-dosage unit in both adult and pediatric patients.
Results

In the base case (Table 2), the annual cost of SCIG treatment per average patient was lower than the IVIG cost by €4266.17 (22.8%). Patients receiving SCIG were estimated to lose fewer hours of work and school time per year as a result of treatment administration and associated travel compared with those receiving IVIG (79.2 vs 101.1 h, respectively). This contributed to lower annual indirect costs, in terms of work productivity for working adult patients and working parents/guardians of pediatric patients receiving SCIG, compared with IVIG (Δ: – €396.73). Hospital administration (Δ: – €2688.03) and IG costs as a function of dosage (Δ: – €1927.47) were the main factors affecting the difference in direct costs (Online Resource 5). These factors were offset somewhat by the costs of training for home administration (Δ: – €694.90) and dispensing (Δ: – €58.27), which did not apply to IVIG (Online Resource 5). When stratified by age groups, total annual costs for SCIG were lower for both pediatric (Δ: – €2521.96) and adult (Δ: – €1744.21) patients compared with those for IVIG (Table 3).

Scenario analyses

The scenario analyses (Table 4) were generally consistent with the base-case analysis. In scenario 1, which accounted for SEFH guidelines to round doses down to the nearest vial in adult patients and up in pediatric patients, the annual cost of

---

Table 2 Base-case analysis for PID: total annual cost and time consumed per average patient for IVIG and SCIG

|                | SCIG       | IVIG       | Difference |
|----------------|------------|------------|------------|
| Total cost (€) | 14,465.63  | 18,731.81  | – 4266.17  |
| Direct healthcare costs | 14,390.90  | 18,260.35  | – 3869.45  |
| Indirect costs  | 74.73      | 471.45     | – 396.73   |
| Total time (h) | 79.24      | 101.10     | – 21.86    |
| Work time      | 5.32       | 33.58      | – 28.26    |
| School time    | 4.98       | 31.70      | – 26.72    |
| Leisure time   | 68.94      | 35.82      | 33.12      |

IVIG intravenous immunoglobulin, PID primary immunodeficiency diseases, SCIG subcutaneous immunoglobulin

Table 3 Base-case analysis for PID by age group: total annual cost and time consumed per average patient for IVIG and SCIG

|                | SCIG        | Pediatric (≤ 18 years) | IVIG        | Pediatric (≤ 18 years) | Difference |
|----------------|-------------|------------------------|-------------|------------------------|------------|
| Adults (≥ 19 years) | 9014.31     | 5451.32                | 10,758.52   | 7973.29                | – 1744.21  |
| Direct healthcare costs | 8984.15     | 5406.76                | 10,570.76   | 7689.59                | – 1586.62  |
| Indirect costs  | 30.16       | 44.57                  | 187.76      | 283.70                 | – 157.60   |
| Total time (h) | 30.83       | 48.41                  | 37.70       | 63.40                  | – 25.70    |
| Work time      | 2.15        | 3.17                   | 13.37       | 20.21                  | – 6.84     |
| School time    | 0.00        | 4.98                   | 0.00        | 31.70                  | – 26.70    |
| Leisure time   | 28.68       | 40.26                  | 24.33       | 11.49                  | 4.36       |

IVIG intravenous immunoglobulin, PID primary immunodeficiency diseases, SCIG subcutaneous immunoglobulin

Table 4 Scenario analyses: total annual cost and time consumed per average patient for IVIG and SCIG

|                | Scenario 1a | Scenario 2b |
|----------------|-------------|-------------|
| Total cost (€) | 14,745.11   | 14,987.42   |
| Direct healthcare costs | 14,670.38   | 14,912.69   |
| Indirect costs  | 74.73       | 74.73       |
| Total time (h) | 79.24       | 79.24       |
| Work time      | 5.32        | 5.32        |
| School time    | 4.98        | 4.98        |
| Leisure time   | 68.94       | 68.94       |

|                | SCIG       | IVIG       | Difference |
|----------------|------------|------------|------------|
| Total cost (€) | 14,987.42  | 19,095.36  | – 4107.95  |
| Direct healthcare costs | 14,912.69  | 18,623.91  |
| Indirect costs  | 74.73      | 74.73      | – 396.73   |
| Total time (h) | 79.24      | 79.24      | – 21.86    |
| Work time      | 5.32       | 5.32       | – 28.26    |
| School time    | 4.98       | 4.98       | – 26.72    |
| Leisure time   | 68.94      | 68.94      | 33.12      |

€ euro, h hour, IVIG intravenous immunoglobulin, SCIG subcutaneous immunoglobulin

aScenario 1: vials adjusted down to the nearest lower dosage in adult patients and the nearest higher dosage in pediatric patients

bScenario 2: vials adjusted up to the nearest higher dosage in both adult and pediatric patients
SCIG per average patient (€14,745.11) was 21.8% less than that of IVIG (€18,853.04; Δ: – €4107.93). In scenario 2, which assumed that, in real clinical practice, doses would be rounded up for both adult and pediatric patients, the annual cost of SCIG per average patient (€14,987.42) was 21.5% less than that of IVIG (€19,095.36; Δ: – €4,107.95). In both scenarios, the estimated work, school, and leisure time lost as a result of treatment administration and associated travel and indirect costs were the same as for the base case.

Discussion

In this cost-minimization model of IGRT therapies for PID in Spain, the annual cost of SCIG treatment per average patient was approximately one-fifth less than that of IVIG. This difference was largely driven by lower annual hospital administration costs and IG cost as function of dosage associated with SCIG, but was slightly offset by training costs, which did not apply to IVIG. It should be noted that differences in IG costs were mainly due to differences in SCIG and IVIG dosages rather than IG unit costs. Results of both dose-adjustment scenario analyses (i.e., implementing resource-sparing dose adjustments for adults or rounding doses up to the nearest vial for both adults and children) supported the finding from the base case that SCIG was less expensive than IVIG.

A consistent theme has emerged in literature that SCIG administered at home is less expensive than hospital-based IVIG. Analyses using real-world cost data from France, Switzerland, Japan, and Canada have all estimated lower costs of SCIG versus IVIG [30–33]. In a French study using a real-world study sample (N = 36), SCIG was 25% less expensive than IVIG because administered SCIG doses were lower than anticipated [30]. A cost-minimization analysis from the Swiss healthcare system perspective found that a total savings of €8,897 per patient could be achieved over 3 years by switching from IVIG administered monthly in an outpatient setting to SCIG administered weekly in the patient’s home [33]. In a Japanese study, patients who switched from IVIG to SCIG had 60% lower productivity loss, resulting in a cost reduction of 10,875 Japanese yen per patient per month [32]. This is generally consistent with the finding in the present analysis that patients receiving SCIG would lose fewer work hours per year because the treatment is self-administered at home; hence, indirect costs would be lower than for patients receiving IVIG. A Canadian study found that over 1 year, average hospital costs were lower for home-based SCIG ($1,836) than for hospital-based IVIG ($4,187), and average physician visit costs were lower for SCIG ($84) than for IVIG ($744) [31]. Our analysis further supports the lower direct and indirect costs of home-based SCIG compared with hospital-based IVIG in the setting of the SNS.

Our analysis estimates higher indirect costs for pediatric patients than for adult patients. This is based on author consensus that pediatric patients will generally have parents or caregivers who are not retired, while a proportion of adult patients will be over 65 years old and retired. Therefore, the loss of work activity measured using indirect costs was assumed to be higher for pediatric patients compared to adult patients. A systematic review and meta-analysis of literature on HRQoL in children and adults with PID highlights the need for developing PID-specific instruments to better evaluate the burden of this disease [34].

In contrast to the real-world analyses of SCIG versus IVIG costs, the present cost-minimization analysis did not use real-world administered dosages to model costs. However, to approximate real-world usage, we assumed, in scenario 2, that dosages were likely to be rounded up to the nearest vial in all patients. Furthermore, the present analysis models the combined costs of conventional and facilitated SCIG, which are dosed at different frequencies. The French, Swiss, and Japanese studies assessed the costs of conventional SCIG only, which typically is dosed weekly [30, 32, 33]. We assumed that, during maintenance therapy, conventional SCIG would be administered every 1 to 2 weeks and facilitated SCIG would be administered every 4 weeks. If the difference in dosing frequency between conventional and facilitated SCIG had been considered in the present analysis, the differences in costs would likely have been greater for facilitated SCIG due to the lower frequency of infusions.

The economic crisis of 2008–2009 and subsequent legislative reforms enacted in 2012 have changed the landscape of healthcare spending in Spain. Public spending on healthcare decreased by 12.2% between 2009 and 2015 [35]. Furthermore, average per capita medical expenditures on drugs and medical appliances increased from €365 in 2006 to €427 in 2015, most likely owing to pharmacy cost-sharing reforms [35]. In light of the limited resources available, home-based administration of SCIG in patients with PID warrants attention for its potential to reduce healthcare costs. In the present study, we showed that switching from hospital-based IVIG to home-based SCIG in Spain is potentially cost-saving, consistent with findings in other countries [30–33].

This study had certain strengths and limitations. Although the analysis did not use cost data from claims or other real-world sources, the model inputs and assumptions were based on the real-world experiences of experts and referenced international guidelines. Sensitivity analyses were limited to IG usage scenarios based on clinical guidelines. Only IG products that are approved and reimbursed by the SNS were included. The use of other IG products is marginal and would have had minimal impact on the results. Finally, this
analysis was based on Spanish national prices and may not reflect regional differences in costs.

**Conclusions**

The findings of this cost-minimization analysis suggest that SCIG is a cost-saving alternative to IVIG for PID in the Spanish healthcare setting; the main factors driving the difference in costs were hospital administration and IG cost as a function of dosage. Patients who receive SCIG can expect to spend fewer hours per year administering IG treatments and traveling to the hospital; consequently, these patients lose fewer hours of work and school than do those who receive IVIG. Together, with patient clinical characteristics, tolerability, preferences, and values, healthcare providers and patients can consider the economic impact of SCIG and IVIG when making treatment decisions.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10198-021-01378-x.

**Acknowledgements** Karen Kartyka of Oxford PharmaGenesis Inc., Newtown, PA, USA, provided medical writing and editorial support, which was funded by Takeda Development Center Americas, Inc. This study was funded by Shire, a Takeda company. Date of original submission: Nov 23, 2020. Date of resubmission: Aug 10, 2021.

**Author’s contributions** Conception and design of the manuscript: Laia Alsina, Miguel Ángel Casado, Luis Ignacio González-Granado, J. Bruno Montoro, Pedro Moral Moral, Olaf Neth, Itziar Oyagüez, Marta Ortiz Pica, Silvia Sánchez-Ramón; Drafting, revision, approval of the submitted manuscript: Laia Alsina, Miguel Ángel Casado, Luis Ignacio González-Granado, J. Bruno Montoro, Itziar Oyagüez, Marta Ortiz Pica, María Presa, Silvia Sánchez-Ramón; Analysis and interpretation of the data: Miguel Ángel Casado, J. Bruno Montoro, Itziar Oyagüez, Marta Ortiz Pica, María Presa, Silvia Sánchez-Ramón; Data collection: Miguel Ángel Casado, Itziar Oyagüez, Marta Ortiz Pica, María Presa, Silvia Sánchez-Ramón; Statistics: Marta Ortiz Pica, María Presa, Silvia Sánchez-Ramón.

**Funding** Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was funded by Shire, a Takeda company.

**Availability of data and material** Not applicable.

**Code availability** Not applicable.

**Declarations**

**Conflict of interest** J. Bruno Montoro reports grants and consultant fees from Biostest, CSL Behring, Grifols, Octapharma, and Shire, a Takeda company, during the conduct of the study. Olaf Neth has been an invited speaker for CSL Behring, Grifols, and Shire, a Takeda company. Marta Ortiz Pica reports research grants and consultant fees from Shire, a member of the Takeda group of companies. Laia Alsina has been an invited speaker for Binding Site, CSL Behring, and Shire, a Takeda company. Luis Ignacio González-Granado has been an invited speaker for CSL Behring and Shire, a Takeda company. Silvia Sánchez-Ramón has served as speaker, consultant, and advisory board member for, or has received research funding from, Biotest, CSL Behring, Grifols, Octapharma, and Shire, a Takeda company. Itziar Oyagüez, Miguel Ángel Casado, and María Presa are employees of Pharmacoconomics and Outcomes Research Iberia, a consultant company specialized in economic evaluation of health technologies, which has received unrestricted funding for development of the analysis. No funding has been received in relation with the authorship of the present manuscript. Pedro Moral Moral reports no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Tangye, S.G., Al-Herz, W., Bousfiha, A., et al.: Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J. Clin. Immunol. 40, 24–64 (2020)
2. McCusker, C., Upton, J., Warrington, R.: Primary immunodeficiency. Allergy. Asthma Clin. Immunol. 14, 61 (2018)
3. Srivastava, S., Wood, P.: Secondary antibody deficiency—causes and approach to diagnosis. Clin. Med. (London) 16, 571–576 (2016)
4. European Society for Immunodeficiencies. ESID Database Statistics. (2019) Available from: https://esid.org/Working-Parties/Registry/ESID-Database-Statistics. Accessed 6 May 2019.
5. Abolhassani, H., Sadaghiani, M.S., Aghamohammadi, A., et al.: Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis. J. Clin. Immunol. 32, 1180–1192 (2012)
6. Chapel, H.M., Spickett, G.P., Ericson, D., et al.: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol. 20, 94–100 (2000)
7. Kobrynski, L.: Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics 6, 277–287 (2012)
8. Wasserman, R.L., Melamed, L., Stein, M.R., et al.: Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol. 130, 951–7.e11 (2012)
9. HyQvia 100 mg/ml solution for infusion for subcutaneous use—summary of product characteristics. (2020) [cited 2021]; Available from: https://www.medicines.org.uk/emc/product/9197/smpc
10. HYQVIA, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase [prescribing information]. Baxalta US Inc.: Lexington, MA, (2021)
11. Bookbinder, L.H., Hofer, A., Haller, M.F., et al.: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control Release. 114, 230–241 (2006)
12. Frost, G.I.: Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv. 4, 427–440 (2007)

13. Wasserman, R.L.: Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 6, 553–567 (2014)

14. Shrestha, P., Karmacharya, P., Wang, Z., et al.: Impact of IVIG vs SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: a systematic review and meta-analysis of clinical studies. World Allergy Organ J. 12, 100068 (2019)

15. Ortega A, M.R., Fraga MD, López-Briz E, Puigventós F Guía de evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos [Guidelines for economic evaluation and budget impact analysis in drug evaluation reports]. (2016).

16. Fernández C, L.H., Vrotsou K, Arestí U, Rica I, Sánchez E Estudio de Crecimiento de Bilbao. [Bilbao Growth Study]. Curvas y Tablas de Crecimiento (Estudio transversal) [Growth Curves and Tables (transversal study)] [Internet]. (2011).

17. Instituto Nacional de Estadística. INEbase: Employment rates per sex and age. (2017). Available from: http://www.ine.es/dynt3/inebase/es/index.htm?padre=982&capsel=984. Accessed 10 Apr 2018.

18. Bonilla, F.A., Khan, D.A., Ballas, Z.K., et al.: Practice parameter for the diagnosis and management of primary immunodeficiency. J. Allergy Clin. Immunol. 136(186–205), e1-78 (2015)

19. Perez, E.E., Orange, J.S., Bonilla, F., et al.: Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy Clin. Immunol. 139, S1–S46 (2017)

20. Wimperis, J., Lunn, M., Jones, A., et al., Clinical guidelines for immunoglobulin use. Department of Health. (2011)

21. CUVITRU, Immune Globulin Subcutaneous (Human), 20% Solution [prescribing information]. Baxalta US Inc.: Lexington, MA, (2021)

22. GAMMAGARD LIQUID, Immune globulin infusion (human), 10% solution [prescribing information]. Baxalta US Inc.: Lexington, MA, (2021)

23. Kerr, J., Quinti, I., Eibl, M., et al.: Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front. Immunol. 5, 629 (2014)

24. Oblikue Consulting. eSalud database on health costs. (2018). Available from: http://www.oblikue.com/bddcostes/. Accessed 25 Sep 2018.

25. Kearns, S., Kristofek, L., Bolgar, W., et al.: Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the IDEAL patient registry. J. Manag. Care Spec. Pharm. 23, 400–406 (2017)

26. Ministerio de Sanidad, Consumo y Bienestar Social [Ministry of Health, Consumer Affairs and Social Welfare], Relación informativa de medicamentos afectados por las deducciones establecidas en el Real Decreto Ley 8/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducción del déficit público. (2018). Available from: https://www.mscbs.gob.es/profesionales/farmacia/pdf/DeduccionesSeptiembre18.pdf Accessed: 26 Sep 2018.

27. Instituto Nacional de Estadística. INEbase: Quarterly survey on labour costs. Series by autonomous region and cost component. (2018). Available from: http://www.ine.es/jaxiT3/Tabla.htm?t=11220. Accessed: 10 Apr 2018.

28. Consejo General de Colegios Oficiales de Farmacéuticos [General Pharmaceutical Council of Spain]. Healthcare Information Database—Bot Plus 2.0. 2018. Available from: https://botplusweb.portalfarma.com/. Accessed 25 Sep 2018.

29. Sociedad Española de Farmacia Hospitalaria [Spanish Hospital Pharmacy Society]. Guía clínica para el uso de inmunoglobulinas [Clinical Guidelines for the Use of Immunoglobulins]. Adaptation for Spain. (2011). Available from: https://www.sefh.es/biblioteca/virtual/Guia_IGH/Guia_Immunoglobulinas.pdf. Accessed 20 Mar 2018.

30. Beault, J., Levy, P., Millet, V., et al.: Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin. Exp. Immunol. 160, 240–245 (2010)

31. Fu, L.W., Song, C., Isaranuwatchai, W., et al.: Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis. Ann. Allergy Asthma Immunol. 120, 195–199 (2018)

32. Igarashi, A., Kanegane, H., Kobayashi, M., et al.: Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Clin. Ther. 36, 1616–1624 (2014)

33. Perraudin, C., Bourdin, A., Spertini, F., et al.: Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program. J. Clin. Immunol. 36, 502–510 (2016)

34. Peshko, D., Kulbachinskaya, E., Korsunskiy, I., et al.: Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J. Allergy Clin. Immunol. Pract. 7, 1929-1957. e5 (2019)

35. Bernal-Delgado, E., Garcia-Armesto, S., Oliva, J., et al.: Spain: health system review. Health Syst.Transit. 20, 1–179 (2018)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.